Overview

A Clinical Trial of 3 Doses of PRAX-944 in Participants With Essential Tremor

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the tolerability, safety, and efficacy of 20, 60, and 120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor. Blood levels of PRAX-944 will also be measured throughout the trial.
Phase:
Phase 2
Details
Lead Sponsor:
Praxis Precision Medicines
Treatments:
Pramoxine